Cormorant Asset Management, LP Galapagos Nv Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$96.85 - $148.25 $12.6 Million - $19.3 Million	-130,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$122.47 - $213.56 $3.79 Million - $6.6 Million	30,925 Added 31.21%	130,000 $18.5 Million
Q2 2020 Aug 14, 2020	BUY	$185.52 - $231.25 $87,565 - $109,150	472 Added 0.48%	99,075 $19.5 Million
Q1 2020 May 15, 2020	SELL	$143.0 - $274.03 $199,771 - $382,819	-1,397 Reduced 1.4%	98,603 $19.7 Million
Q4 2019 Feb 14, 2020	SELL	$146.12 - $215.82 $7.31 Million - $10.8 Million	-50,000 Reduced 33.33%	100,000 $20.9 Million
Q3 2019 Nov 14, 2019	SELL	$130.44 - $187.64 $3.26 Million - $4.69 Million	-25,000 Reduced 14.29%	150,000 $22.9 Million
Q2 2019 Aug 14, 2019	SELL	$111.45 - $128.93 $13.9 Million - $16.1 Million	-125,000 Reduced 41.67%	175,000 $22.6 Million
Q1 2019 May 15, 2019	BUY	$89.61 - $117.78 $26.9 Million - $35.3 Million	300,000 New	300,000 $35 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.